Main Uses of Klaricid XL

Klaricid XL is an antibiotic containing the active substance clarithromycin in a modified-release formulation. It belongs to a group of medicines known as macrolide antibiotics. These medications work by inhibiting the growth of certain types of bacteria responsible for infections in different parts of the body.

This medication is primarily used to treat bacterial infections such as:

• Chest infections: This includes conditions like bronchitis and pneumonia.
• Throat and sinus infections: Such as sinusitis and pharyngitis.
• Skin and soft tissue infections: Including conditions like folliculitis, cellulitis, or erysipelas.

How it Works

Clarithromycin works by interfering with the protein synthesis of susceptible bacteria. By preventing the bacteria from producing essential proteins, the medication stops their growth and spread, allowing the body's immune system to eliminate the infection.

Benefits of the Modified-Release Formulation

The "XL" designation indicates that the tablet is a modified-release (extended-release) version of the medication. This formulation is designed to release the active ingredient slowly as it passes through the digestive system.

The primary benefits of this delivery method include:

• Consistent Medication Levels: It helps maintain a steady concentration of the antibiotic in the bloodstream over a 24-hour period.
• Once-Daily Dosing: Because the medication is released gradually, it typically allows for a simplified schedule compared to immediate-release formulations.

Klaricid XL is only effective against bacterial infections; it does not treat viral infections, such as the common cold or the flu.

Regulatory References

1. FDA DailyMed Clarithromycin Extended-Release Information

Official Eligibility Rules for Klaricid XL

The eligibility for Klaricid XL (clarithromycin extended-release) is strictly defined by regulatory labeling, which governs the approved population and lists absolute prohibitions based on cardiac risk factors, organ function, and allergy status.

Eligibility Status	Defined Population
Allowed	Adults (age 18 and over) only.
Not Recommended	Children under 12 years of age (the extended-release tablet form is unsuitable).
Use with Caution	Patients with Myasthenia Gravis, severe cardiac insufficiency, or moderate renal impairment.

Absolute Contraindications

The medicine must not be used in patients with a known allergy to clarithromycin or any other macrolide antibiotic. It is prohibited for individuals with a history of QT prolongation or ventricular cardiac arrhythmia, and those with uncorrected low potassium or magnesium levels. The fixed dose of the XL tablet makes it contraindicated for patients with severe renal impairment (creatinine clearance <30 mL/min), or severe liver failure combined with kidney impairment. Use is also prohibited if there is a history of clarithromycin-induced cholestatic jaundice or if specific concomitant medications (e.g., cisapride, pimozide) are being taken. Use during pregnancy is not recommended unless clinical circumstances allow no alternative.

Interactions with other medicines and products

Clarithromycin, the active ingredient in Klaricid XL, is documented as a strong inhibitor of the CYP3A4 enzyme and a P-glycoprotein (P-gp) inhibitor, which forms the basis for numerous drug interactions. These mechanisms can lead to a significant increase in the plasma concentration of co-administered medicines.

Formal Interaction Restrictions

Co-administration is contraindicated with several medicines due to the high risk of serious adverse events. These include Astemizole, Cisapride, Pimozide, and Terfenadine, which carry a risk of QT prolongation. The combination with Lovastatin or Simvastatin is also prohibited due to the risk of rhabdomyolysis. Additionally, Ergot alkaloids are contraindicated because of the potential for acute ergot toxicity.

Clinically Significant Interactions

Interacting Substance	Official Interaction Outcome
Oral Anticoagulants (Warfarin)	Risk of **serious hemorrhage** and elevated **INR** or **Prothrombin time**.
Oral Hypoglycemic Agents / Insulin	Risk of **significant hypoglycemia**.
Digoxin	Potential for **increased Digoxin exposure** due to P-gp inhibition.

Administration Conditions

Klaricid XL extended-release tablets must be taken with food, as fasting administration results in officially documented lower drug exposure. Furthermore, administration with Zidovudine requires a 2-hour separation between doses.

Molecular Blockade of Bacterial Protein Synthesis

Clarithromycin acts through the inhibition of protein synthesis in susceptible bacteria. It achieves this by binding specifically and reversibly to the 50S ribosomal subunit , which is the cellular machinery bacteria rely on to build essential proteins. This molecular blockade stops the ribosome from moving along the messenger RNA (translocation), thereby halting the elongation of new peptide chains. This action is primarily bacteriostatic, preventing the bacteria from growing and multiplying, which results in the suppression of the microbial population.

Enhanced Action via Active Metabolite Synergy

Clarithromycin is metabolized in the body to form an active compound called 14-(R)-hydroxy clarithromycin. This metabolite is a functional antimicrobial agent in its own right and operates in synergy with the parent drug. The combined effect of both the parent compound and its active metabolite provides a sustained and complementary mechanism against the microbial target, contributing to the physiological effect of bacterial suppression.

Mechanistic Limitations (Bacterial Resistance)

The drug's mechanism is constrained by specific molecular mechanisms of bacterial resistance. The primary limitations arise when bacteria acquire genes that either modify the drug’s target site (through methylation of the 23S rRNA) or activate efflux pumps. Both mechanisms prevent the Clarithromycin molecule from achieving the necessary concentration at the 50S ribosomal subunit, which allows protein synthesis to resume. This explains the mechanistic boundaries of the drug’s action.

How to Use Klaricid XL: Official Administration Guidelines

Klaricid XL (clarithromycin extended-release tablet) is an oral formulation designed for once-daily administration in adults. The usage protocol is designed to ensure the sustained-release mechanism functions as intended and maintains consistent systemic exposure.

---

Administration Scope

Property	Instruction
Route of Administration	Oral route (by mouth) only.
Dosing Schedule (Adults)	Standard adult dose is 1000 mg per day, typically administered as two 500 mg tablets.
Timing in relation to Meals	Tablets must be taken with food to ensure adequate drug absorption from the extended-release formulation.
Special Procedural Conditions	The tablets must be swallowed whole; they are not to be crushed, chewed, or broken, as this would compromise the slow-release action.

---

Population-Specific Constraints

Guidelines impose limitations on the use of the extended-release tablet in specific patient groups. The tablet is not recommended for children under 12 years of age, who are directed toward alternative formulations. Furthermore, the extended-release tablet is contraindicated in adults with severe renal impairment (creatinine clearance less than 30 mL/min) because the 500 mg strength does not permit the necessary dose reduction.

Course Duration and Missed Doses

Treatment follows a fixed course duration which is typically 7 to 14 days, determined by the specific infection being managed. If a dose is missed, the standard procedure is to resume the normal schedule, skipping the missed dose if it is almost time for the next scheduled dose.

Research Evidence for Acute Respiratory and Sinus Infections

The clinical research for Klaricid XL has primarily focused on conditions characterized by episodic or acute changes related to the lungs, airways, and sinuses, such as acute exacerbations of chronic bronchitis, community-acquired pneumonia, and acute maxillary sinusitis. Studies conducted during periods of increased symptom activity have included Randomized Controlled Trials (RCTs) and Comparative Phase III Clinical Trials to explore the extended-release formulation’s characteristics relative to other agents. Researchers monitored outcomes related to systemic or functional imbalance, including measurements of rates of monitored clinical endpoints and Bacteriological Clearance. Research examined patterns related to measured changes in patient outcomes when the extended-release formulation was assessed against its immediate-release counterpart over short, defined time intervals.

---

Studies in Specialized Infection Contexts

Klaricid XL was also studied for its application as part of a multi-drug combination regimen for conditions such as Helicobacter pylori infection (associated with duodenal ulcers) and Mycobacterium avium Complex (MAC). For these uses, the research explored whether the extended-release formulation achieves comparable drug exposure to the standard version, primarily through Bioequivalence and Pharmacokinetic (PK) studies. For MAC, PK studies reported achieving comparable overall drug exposure (AUC). However, the evidence is limited by the fact that the success of H. pylori therapy is influenced by the entire combination treatment, and MAC evidence relies heavily on PK data rather than dedicated clinical efficacy trials.

---

Evidence Gaps and Research Uncertainty

Research findings apply only to the populations studied, and data for certain groups, such as those with specific severe comorbid conditions, remain insufficient. A primary limitation across the entire research base is that long-term effects are not fully established. Follow-up durations were often limited to just a few weeks after treatment, providing little information regarding the recurrence of infections or the maintenance of functional stability. Furthermore, research is ongoing to fully clarify the contribution of the medicine’s non-antimicrobial properties to the outcomes related to physical discomfort observed in the studies.

Key Studies & References

1. Clarithromycin Extended-Release Tablets, USP: FDA-Approved Labeling (DailyMed)
2. Pharmacokinetics and tolerability of extended-release clarithromycin (2001) [Covers Bioequivalence/AUC data]
3. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (2017) [Context for use in multi-drug regimens]

Common questions about Klaricid XL (FAQ)

Q: What is the active ingredient in Klaricid XL?

The active ingredient in Klaricid XL is clarithromycin. According to official product information, this is an antibiotic medicine that belongs to the macrolide group. It works by stopping the growth of certain types of bacteria that cause infections.

Q: Does Klaricid XL interact with other medications, like simvastatin or midazolam?

Official product information indicates that Klaricid XL has clinically significant interactions with certain medicines. Regulatory documents specifically warn against using it with medicines like simvastatin (used for high cholesterol) and midazolam (used for anxiety or sedation). Regulatory guidance highlights the importance of discussing all current medications with a healthcare provider.

Q: Is Klaricid XL an antibiotic?

Yes, Klaricid XL is an antibiotic. It is classified as a macrolide antibiotic. This means it is used to treat infections caused by specific types of susceptible bacteria.

Q: Can I take Klaricid XL if I have a history of heart rhythm problems?

Regulatory information indicates that Klaricid XL should be used with caution, or may be unsuitable, for people with certain pre-existing heart conditions. These include a history of heart rhythm problems (known as a prolonged QT interval) or a very slow heart rate. Official sources indicate that a prescriber must be informed of an individual's full medical history prior to prescribing this medicine.

Q: What happens if I miss a dose of Klaricid XL?

The official instructions state that a missed dose of Klaricid XL is usually taken as soon as it is remembered. However, if it is almost time for the next dose, regulatory documents state that the missed dose is typically skipped, and the next dose is taken at the regular time. Do not take a double dose to make up for the forgotten tablet.

Q: Is it required to take Klaricid XL with food?

According to the official product information for Klaricid XL prolonged-release tablets, it is generally advised to take the tablet with food. Regulatory guidance suggests taking it with food to aid absorption and potentially reduce gastrointestinal effects. Regulatory documents state that the tablets must be swallowed whole.

Q: Can Klaricid XL be used to treat a viral infection, like a common cold?

Klaricid XL is an antibiotic, and antibiotics are designed to treat bacterial infections. According to official guidelines, this medicine is not effective against viral infections, such as the common cold or flu. Using it for a viral illness is not effective and may contribute to the development of antibiotic resistance.

Storage and Disposal of Klaricid XL

Klaricid XL (Clarithromycin Prolonged-Release Tablets) must be stored and handled according to specific official instructions to maintain its integrity and ensure safety.

Storage Requirements

The medicine must be kept out of the sight and reach of children. Store the tablets in a dry place and protected from light, in the original package until the expiration date. The required storage temperature is below 30 C.

Disposal Instructions

Do not use the tablets after the printed expiry date. Expired or damaged tablets must be returned to a pharmacist for disposal. The medicine must not be disposed of in wastewater or household waste (e.g., sink or toilet).